Health care gaps in the global burden of drug-resistant tuberculosis

被引:15
作者
Cox, V. [1 ]
Cox, H. [2 ,3 ]
Pai, M. [4 ]
Stillo, J. [5 ]
Citro, B. [6 ]
Brigden, G. [7 ]
机构
[1] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, Sch Publ Hlth & Family Med, Cape Town, South Africa
[2] Univ Cape Town, Div Med Microbiol, Cape Town, South Africa
[3] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa
[4] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada
[5] Wayne State Univ, Coll Liberal Arts & Sci, Detroit, MI USA
[6] Northwestern Pritzker Sch Law, Chicago, IL USA
[7] Int Union TB & Lung Dis, Paris, France
关键词
DR-TB diagnostic gaps; DR-TB treatment gaps; DR-TB human rights law; DR-TB new drugs and shorter regimen; XPERT MTB/RIF; TREATMENT OUTCOMES; MDR TUBERCULOSIS; ROLL-OUT; CHILDREN; DIAGNOSIS; MICROSCOPY; MANAGEMENT; SERVICES; LESSONS;
D O I
10.5588/ijtld.18.0866
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The drug-resistant tuberculosis (DR-TB) cascade-from estimated or incident cases to numbers successfully treated or disease-free survival-has long been characterised by sharp declines at each step in the cascade. The losses along the cascade vary across different settings, and the reasons why some countries have a higher burden of DR-TB are complex and multifactorial; broadly, weak health systems, inadequate financing and poverty all impact differential access to DR-TB care. Within a human rights framework that mandates the right to health and the right to benefit from scientific progress, the aim of this review is to focus on describing inequities in access to DR-TB care at critical points in the cascade.
引用
收藏
页码:125 / +
页数:12
相关论文
共 75 条
[1]   Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? [J].
Albert, Heidi ;
Nathavitharana, Ruvandhi R. ;
Isaacs, Chris ;
Pai, Madhukar ;
Denkinger, Claudia M. ;
Boehme, Catharina C. .
EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (02) :516-525
[2]  
[Anonymous], 2014, USE DELAMANID TREATM
[3]  
[Anonymous], 2015, The Paradigm Shift 2016-2020: Global Plan to End TB
[4]  
[Anonymous], 2018, Livelihoods of Visual Artists: 2016 Data Report
[5]  
[Anonymous], 2017, WHO MON XPERT MTB RI
[6]  
[Anonymous], 2013, Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update
[7]   Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients [J].
Aung, K. J. M. ;
Van Deun, A. ;
Declercq, E. ;
Sarker, M. R. ;
Das, P. K. ;
Hossain, M. A. ;
Rieder, H. L. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (10) :1180-1187
[8]   Health systems and the right to health: an assessment of 194 countries [J].
Backman, Gunilla ;
Hunt, Paul ;
Khosla, Rajat ;
Jaramillo-Strouss, Camila ;
Fikre, Belachew Mekuria ;
Rumble, Caroline ;
Pevalin, David ;
Paez, David Acurio ;
Pineda, Monica Armijos ;
Frisancho, Ariel ;
Tarco, Duniska ;
Motlagh, Mitra ;
Farcasanu, Dana ;
Vladescu, Cristian .
LANCET, 2008, 372 (9655) :2047-2085
[9]  
Biehl J, 2016, HEALTH HUM RIGHTS, V18, P209
[10]   Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis [J].
Boyd, R. ;
Ford, N. ;
Padgen, P. ;
Cox, H. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (11) :1173-+